(Date:11/20/2009)...-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasd...ircuit Court of Appeals reversed a U.S. District C... pursue all of its claims against The Lash Group, ...ial. CTI filed a complaint against The Lash Group...t for CTI,s product TRISENOX, in 2007 seeking $22....
(Date:11/19/2009)...stCall/ -- Omeros Corporation (Nasdaq: OMER ) tod...hird quarter ended September 30, 2009. For the thr...d a net loss of $3.9 million, or $1.34 per share, ...4 per share, for the same period in 2008. For the ...reported a net loss of $15.5 million, or $5.29 per...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)...d by latest award for revolutionary hearing aid. ...ber 16, 2009 -- Popular Science Magazine has named...m InSound Medical a winner of its coveted Best of ...p; Chosen from thousands of entra...ng canal for up to four months while providing nat...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3...d, Ph.D., Joins as Chief Executive Officer, MENLO...y, Inc. (FAB), a privately held biotechnology comp...ies B financing. Prior investor SV Life,Sciences (...lta Partners.,The proceeds from the financing will...synthesis technology to produce biologic drugs and...
...urg Regional Education Consortium Promoting Advanc..., Dec. 7 High school and,college students from th...anced technology careers and curriculum through a ...s and the commonwealth., At BioTech Day 2007, hos...chnology, Community and Economic Development Deput...
...D, Calif., Dec. 7 Ardea Biosciences,Inc. (Nasdaq:...ief Executive,Officer, Barry D. Quart, PharmD, wil...eatment" panel discussion at the RBC Capital Marke...er 12, 2007 at 1:30 p.m. (ET) at,the Westin Times ...t of the,presentation and panel discussion will be...
Other Biology Technology:Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 2Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 3Capital Area Biotechnology Partnership Receives $160,000 State Investment 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3Mouse Anti-TUP1 Monoclonal Antibody, Unconjugated, Clone 10 from Exalpha Biologicals, Inc.
Anti-UbcH7 Antibody, Unconjugated from CHEMICON
Mouse Anti-Mouse C5a Receptor (CD88) Monoclonal Antibody, Unconjugated, Clone 10 / 92 from Cell Sciences
Goat Anti-Sarcosine Oxidase Polyclonal Antibody, HRP Conjugated from Abcam
Biology Products: